Metronomic Outpatient-Based Chemotherapy with 5′-DFUR and Low-Dose Cisplatin for Conventional Platinum-Based Chemotherapy-Resistant Advanced Urothelial Cancer

Metronomic Outpatient-Based Chemotherapy with 5′-DFUR and Low-Dose Cisplatin for Conventional Platinum-Based Chemotherapy-Resistant Advanced Urothelial Cancer

Background Metronomic chemotherapy is aimed at lessening the adverse effects of treatment while rendering cancer cells cytostatic. The oral 5-fluorouracil prodrug “5′-DFUR” has been shown to inhibit angiogenesis and is regarded as a good candidate agent for metronomic chemotherapy. Moreover, cisplat...

Full description

Bibliographic Details
Main Authors: Tomohiko Hara, Satoru Yoshihiro, Hideaki Ito, Kazuhiro Nagao, Chietaka Ohmi, Shigeru Sakano, Hideyasu Matsuyama, Katsusuke Naito
Format: Article
Language:English
Published: SAGE Publishing 2007-01-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.4137/CMO.S304

Internet

https://doi.org/10.4137/CMO.S304

Similar Items